Pick your post-JPM buzz: Pfizer eyes Amarin, Biogen shops anyone with 'multiple' phase 3 drugs

The J.P. Morgan Healthcare Conference may be over, but that doesn’t mean the dealmaking is. Often, deals that took shape at the meeting materialize later in the year, and some recent buzz puts Pfizer and Biogen at the center of potential takeovers. Pfizer is reportedly eyeing a buyout of cardiovascular player Amarin, whose fish-oil-derived lipid drug… Read More: Pick your post-JPM buzz: Pfizer eyes Amarin, Biogen shops anyone… »

Harvard research reveals Coke’s fingerprints on health policy in China

A complex network of research funding, institutional ties, and personal influence allowed Coca-Cola, through connections with a nonprofit group, to exert substantial influence over obesity science and policy solutions in China, nudging government policy into alignment with the company’s corporate interests, a Harvard study has found. Professor Susan Greenhalgh’s study reveals not just efforts by… Read More: Harvard research reveals Coke’s fingerprints on health policy in China »

  1. Pages:
  3. 1
  5. 928
  6. 929
  7. 930
  8. 931
  9. 932
  10. 933
  11. 934
  13. 1261